Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Ekso Bionics Holdings (EKSO) Shares Outstanding (2016 - 2026)

Ekso Bionics Holdings has reported Shares Outstanding over the past 14 years, most recently at $2.6 million for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 78.92% to $2.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.6 million, a 78.92% increase, with the full-year FY2024 number at $1.5 million, changed N/A from a year prior.
  • Shares Outstanding reached $3.6 million in Q4 2025 per EKSO's latest filing, up from $2.6 million in the prior quarter.
  • The five-year high for Shares Outstanding was $14.2 million in Q3 2023, with the low at $1.2 million in Q1 2024.
  • The 5-year median for Shares Outstanding is $12.7 million (2021), against an average of $8.4 million.
  • Peak YoY movement for Shares Outstanding: plummeted 91.1% in 2024, then soared 111.96% in 2025.
  • Tracing EKSO's Shares Outstanding over 5 years: stood at $12.7 million in 2021, then increased by 4.26% to $13.2 million in 2022, then grew by 7.82% to $14.2 million in 2023, then crashed by 89.6% to $1.5 million in 2024, then soared by 77.23% to $2.6 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $2.6 million, $2.6 million, and $1.9 million for Q3 2025, Q2 2025, and Q1 2025 respectively.